Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of SHR3824 in Hepatic Impairment
NCT03160014Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jun 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hengrui. Primary endpoints: Area Under the Plasma Concentration-Time Curve at 72 hours and Maximum Plasma Concentration at 72 hours. Status: unknown.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03160014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03160014.